No evidence of benefit for universal screening with 75 g oral glucose tolerance test in polycystic ovary syndrome

Warrick J Inder
Med J Aust 2011; 195 (10): . || doi: 10.5694/mja11.11307
Published online: 21 November 2011

Should the recently published PCOS guidelines be revised?

The recent supplement of the Journal titled “Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline” summarises the full Australian guideline document that was launched at the 2011 Endocrine Society of Australia Annual Scientific Meeting.1 The document is thorough and has been put together meticulously; it covers the major diagnostic and management issues encountered by health professionals looking after patients with this challenging condition. However, the recommendations for metabolic screening included a 2-yearly 75 g oral glucose tolerance test (OGTT) in all women with polycystic ovary syndrome (PCOS), and annual testing for those with an additional risk factor.1 I believe that this screening protocol is not based on evidence and should not be applied universally to women with PCOS.

  • 1 Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, QLD.
  • 2 School of Medicine, University of Queensland, Brisbane, QLD.

Competing interests:

No relevant disclosures.

  • 1. Teede HJ, Misso ML, Deeks AA, et al. Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Med J Aust 2011; 195 (6 Suppl): S65-S112. <MJA full text>
  • 2. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800.
  • 3. Dabadghao P, Roberts BJ, Wang J, et al. Glucose tolerance abnormalities in Australian women with polycystic ovary syndrome. Med J Aust 2007; 187: 328-331. <MJA full text>
  • 4. Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745-2749.
  • 5. Salley KE, Wickham EP, Cheang KI, et al. Glucose intolerance in polycystic ovary syndrome — a position statement of the Androgen Excess Society. J Clin Endocrinol Metab 2007; 92: 4546-4556.
  • 6. Stovall DW, Bailey AP, Pastore LM. Assessment of insulin resistance and impaired glucose tolerance in lean women with polycystic ovary syndrome. J Womens Health (Larchmt) 2011; 20: 37-43.
  • 7. Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva: World Health Organization, 1968. (accessed Oct 2011).
  • 8. Pesant MH, Baillargeon JP. Clinically useful predictors of conversion to abnormal glucose tolerance in women with polycystic ovary syndrome. Fertil Steril 2011; 95: 210-215.
  • 9. Mohlig M, Floter A, Spranger J, et al. Predicting impaired glucose metabolism in women with polycystic ovary syndrome by decision tree modelling. Diabetologia 2006; 49: 2572-2579.
  • 10. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
  • 11. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
  • 12. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
  • 13. Franks S. When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome? Clin Endocrinol (Oxf) 2011; 74: 148-151.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.